OTCMKTS:IMUN Immune Therapeutics (IMUN) Stock Price, News & Analysis $0.09 0.00 (0.00%) (As of 10/19/2023) Add Compare Share Share Today's Range$0.09▼$0.0950-Day Range$0.09▼$0.0952-Week Range$0.07▼$1.30Volume12 shsAverage Volume15,246 shsMarket Capitalization$7.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesStock AnalysisHeadlines Get Immune Therapeutics alerts: Email Address Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Immune Therapeutics Stock (OTCMKTS:IMUN)Immune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is based in Winter Park, Florida.Read More IMUN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMUN Stock News HeadlinesJuly 24 at 5:50 AM | markets.businessinsider.comImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid TumorsJuly 19, 2024 | msn.comStudy identifies unpredicted immune responses to adenoviral COVID-19 vaccinesJuly 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.May 22, 2024 | msn.comImmune-checkpoint inhibitors protect bone by promoting osteogenesis, exploratory study showsMay 21, 2024 | msn.comPesticide concerns prompt recall of nearly 900,000 Yogi Echinacea Immune Support tea bagsMay 21, 2024 | finance.yahoo.comHow BIRM Is Balancing Immune SystemsMay 20, 2024 | msn.comYogi Recalls Immune Support Tea After Reports of Pesticide ContaminationMay 19, 2024 | msn.comImmune checkpoint protein VISTA can directly turn off T-cells during immunotherapy, study finds ...July 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.May 18, 2024 | msn.comResearch finds the protein VISTA directly blocks T cells from functioning in immunotherapyMay 10, 2024 | msn.comChina’s Immune Therapy Stocks Soar as Research Delivers Promising ResultsMay 9, 2024 | msn.comScientists discover how deadly skin cancer evades the human immune systemMay 7, 2024 | msn.comResearchers find B cells drive responses of other immune cells, can be modified to prevent multiple sclerosis symptomsMay 2, 2024 | msn.comResearchers discover how immune B cells hunt down cancer around the bodyMay 2, 2024 | msn.comControlled human infection study paves the way to improving vaccines and therapeutics developmentApril 29, 2024 | markets.businessinsider.comRepertoire Immune Medicines In Strategic Partnership With Bristol Myers SquibbApril 26, 2024 | msn.comExperts develop immune-enhancing therapies to target tuberculosisApril 25, 2024 | benzinga.comEXCLUSIVE: Virax Biolabs Launches Immune Profiling Solutions To Evaluate Adaptive Immunity In Post-Viral SyndromesSee More Headlines Receive IMUN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:IMUN CUSIPN/A CIK1559356 Webwww.immunetherapeutics.com Phone(888) 613-8802FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,540,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-544.75% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-3.10Miscellaneous Outstanding Shares83,660,000Free Float41,335,000Market Cap$7.78 million OptionableNot Optionable Beta0.46 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMs. Kelly O'Brien Wilson (Age 51)Interim CEO, COO & Pres Comp: $53.83kMs. Noreen M. Griffin (Age 70)Exec. VP of Bus. Devel. & CEO Mr. Glen A. Farmer M.B.A. (Age 54)Chief Financial Officer Ms. Cynthia Douglas (Age 50)Company Sec. Dr. Joseph M. Fortunak (Age 68)VP of Global R&D and Chemical Devel. Key CompetitorsAkari TherapeuticsNASDAQ:AKTXEquilliumNASDAQ:EQDaré BioscienceNASDAQ:DAREChina Health IndustriesOTCMKTS:CHHEEnlivex TherapeuticsNASDAQ:ENLVView All Competitors IMUN Stock Analysis - Frequently Asked Questions How have IMUN shares performed this year? Immune Therapeutics' stock was trading at $0.0930 at the beginning of the year. Since then, IMUN shares have increased by 0.0% and is now trading at $0.0930. View the best growth stocks for 2024 here. How do I buy shares of Immune Therapeutics? Shares of IMUN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Immune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immune Therapeutics investors own include Northwest Biotherapeutics (NWBO), Alexion Pharmaceuticals (ALXN), AK Steel (AKS), Galiano Gold (AKG), Agritek (AGTK), Agenus (AGEN) and Affymetrix (AFFX). This page (OTCMKTS:IMUN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immune Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.